课题基金 / 基金详情

Bridging discovery to clinic: from biomarkers to therapeutic developments in ovarian cancer

Bridging discovery to clinic: from biomarkers to therapeutic developments in ovarian cancer
将发现与临床联系起来:从生物标志物到卵巢癌的治疗进展
批准号:
333010
负责人:
Mes-Masson Anne-Marie
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2015
资助国家:
加拿大
项目状态:
已结题
起止时间:
2015-05-01 至 2016-05-01

项目摘要

项目成果

Mes-Masson Anne-Marie的其他基金

相似基金

相关文献

中文摘要
翻译
在女性中,卵巢癌是北美癌症相关死亡的第五大原因,也是第二大常见妇科癌症。大部分卵巢癌患者无症状,超过70%的卵巢癌患者在疾病晚期被诊断出来
英文摘要
In women, ovarian cancer is the fifth leading cause of cancer-related deaths in North America and the second most common gynecological cancer. Largely asymptomatic, over 70% of patients with ovarian cancer are diagnosed at an advanced stage of the disease
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unveiling the Role of Cellular Aging in Postmenopausal Syndrome: Rationale for Senolytic-Based Strategies to Enhance Women's Health
Targeting cellular aneuploidy through modulation of Ran GTPase in epithelial ovarian cancer
Development and validation of a multiplex blood-based assay for the early detection of ovarian cancer.
海外基金